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Manuscript
Commentary 
New glucose lowering agents for type 2 diabetes are expensive compared to older drugs, so it is 
important for patients, those treating them and payers that information used to guide treatment 
decisions is based on a clear analysis of the benefits and risks of each drug.  Whilst the benefit of 
glucose lowering to reduce microvascular complications was established in the UKPDS trial (1), there 
remains uncertainty in relation to the risk of cardiovascular disease, highlighted by the controversy 
about thiazolidinediones, particularly rosiglitazone, and the adverse effects on cardiovascular death 
observed in the ACCORD trial of intensive glucose lowering in patients with longstanding diabetes 
(2).   As a result, regulatory agencies now require evidence (based on adjudicated outcomes from 
phase 3 trials) that the risk of cardiovascular harm is low for all new glucose lowering therapies 
before a drug is made available, and usually also require a post-marketing cardiovascular safety trial.  
The results of most recent trials with the DPP-IV inhibitor class of drugs and of one trial with a GLP-1 
receptor agonist have largely confirmed the safety of these treatments, with the exception of a 
signal for increased heart failure hospitalisation with saxagliptin, but not demonstrated 
cardiovascular benefit (3-6).  The latest class of glucose-lowering therapies, the sodium-glucose co-
transporter 2 (SGLT2) inhibitors, inhibit glucose reabsorption from the proximal renal tubules 
resulting in glycosuria.  This results in lowering of blood glucose, weight loss and (partly as a result of 
a transient natriuresis) blood pressure reduction; they do however modestly increase LDL 
cholesterol and increase the risk of genital fungal infections.  Several other safety concerns have also 
been raised, including the risk of bacterial urinary tract infections, bone fractures, hypotension, 
ketoacidosis and bladder and breast cancers.  The regulatory assessment of benefit / risk, including 
cardiovascular safety meta-analyses based on phase 3 data, allowed marketing of these drugs, but 
the first of the cardiovascular outcome trials, the EMPA-REG trial, which studied 7020 patients with 
type 2 diabetes and pre-existing cardiovascular disease treated for 3.1 years, found a reduction 
(hazard ratio, HR 0.86) in a composite of myocardial infarction, non-fat stroke and cardiovascular 
death with empagliflozin treatment compared with placebo.  Interestingly there was no significant 
reduction of myocardial infarction and a trend for increased risk of stroke, so the overall benefit was 
largely due to a reduction in cardiovascular death (HR 0.62).  There was also a striking reduction in 
heart failure hospitalisation compared to placebo (HR 0.65). (7). These results raise several questions 
about mechanisms, especially as there did not seem to be a reduction in atherosclerotic disease, and 
also as to whether this is a class effect and if beneficial effects might extend to patients without pre-
existing cardiovascular disease.  In this issue of the journal, Wu and colleagues present a meta-
analysis using all available data from published clinical trials and regulatory submissions to provide 
the most comprehensive analysis of the benefit / risk of the SGLT2 inhibitor class available to date 
(8).  Despite being strongly influenced by the EMPA-REG data (which contributed three-quarters of 
the CV events to the analysis), the study suggests these benefits extend to other drugs in the class, 
and largely confirms a null effect for most of the other safety concerns with the exception of genital 
infections.  There are some limitations to this approach, as the analysis does not distinguish between 
studies that included special populations such as those with renal impairment that are currently 
excluded from the license and also includes some studies that used doses above those that are 
currently recommended; nevertheless this should, if anything exaggerate harms, so again provides 
some reassurance.  Should we now embrace the use of SGLT2 inhibitors as glucose-lowering drugs 
that provide cardiovascular benefit for all patients with type 2 diabetes?  Probably not yet.  Much of 
the benefit seems to relate to heart failure, and as the effects seen are too rapid to be due to a 
reduction in atherosclerotic disease mechanistic studies to fully understand the effects of SGLT2 
inhibitors on the heart are essential.  Ongoing trials include the DECLARE TIMI-58 trial with 
dapagliflozin which includes over 17,000 patients, and the CANVAS and CANVAS-R studies with 
canagliflozin together include over 6000 patients, of which a significant proportion have CV risk 
factors but not pre-existing cardiovascular disease.  These studies will provide essential additional 
information about the risks and benefits of SGLT2 inhibitors in these lower risk patients, where the 
risk of heart failure is likely to be much lower.  There is also the intriguing potential for 
renoprotection, brought into sharp focus by the EMPA-REG results which show a reduction in the 
composite of time to doubling of serum creatinine, the development of end stage renal failure or 
death in patients with an eGFR < 60 ml/min (HR 0.54) (9). The results of the CREDENCE and CANVAS-
R studies with canagliflozin that have primary renal outcomes should be informative in this respect.  
The SGLT2 inhibitors may represent the start of a new era for diabetes treatment, but we should 
await the results of these ongoing trials before adopting widespread use in the expectation of 
cardiovascular benefit, despite the encouraging data from this latest meta-analysis. 
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